Commercially available CAR T products such as Yescarta and Kymriah have shown the power of cell therapies to eradicate deadly cancers even after several failed lines of treatment. While early cell therapies offer new hope, they rely on patient-derived cells and access to them is limited. Several factors reduce patient eligibility, including cell volume and quality criteria, time and resources needed for manufacturing, and the level of medical facility required for patient care. Allogeneic cell therapies have the potential to overcome many of these challenges because they can be produced in large, quality-controlled lots and made available immediately once prescribed. This panel will review the potential advantages of readily available off-the-shelf cell therapy products and discuss what’s required to make them a reality and open the door for many more high-need patients to benefit from cell therapy.